Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced vs Standard Dose PTCY in Haploidentical Transplantation
NCT06000982Phase 3Not yet recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cyclophosphamide in graft-versus-host disease (GVHD), sponsored by Shanghai Jiao Tong University School of Medicine. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06000982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06000982.